^
    PanTracer Tissue, the next evolution of Neo Comprehensive - Solid Tumor, offers a tissue-based CGP approach, providing deep insights into tumor genome from solid-tumor biopsy samples, helping oncologists make precise, actionable therapy decisions. Supports guideline‑driven biomarkers for therapy selection and clinical trial eligibility. DNA + RNA sequencing enhances detection of complex alterations like gene fusions
    Cancer:
    Solid Tumor
    Method:
    RNA/DNA-based molecular screening test